
## David Calvo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6553682/publications.pdf Version: 2024-02-01



ΠΑΥΙΟ CALVO

#	Article	IF	CITATIONS
1	Cardiac fibrillation: From ion channels to rotors in the human heart. Heart Rhythm, 2008, 5, 872-879.	0.3	186
2	Mechanisms of Fractionated Electrograms Formation in the Posterior Left Atrium During Paroxysmal Atrial Fibrillation in Humans. Journal of the American College of Cardiology, 2011, 57, 1081-1092.	1.2	105
3	Atrial Septopulmonary Bundle of the Posterior Left Atrium Provides a Substrate for Atrial Fibrillation Initiation in a Model of Vagally Mediated Pulmonary Vein Tachycardia of the Structurally Normal Heart. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 175-183.	2.1	87
4	Atrioventricular Conduction Disturbance Characterization in Transcatheter Aortic Valve Implantation With the CoreValve Prosthesis. Circulation: Cardiovascular Interventions, 2011, 4, 280-286.	1.4	81
5	Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia. Journal of the American College of Cardiology, 2022, 79, 1441-1453.	1.2	75
6	Mechanisms and Drug Development in Atrial Fibrillation. Pharmacological Reviews, 2018, 70, 505-525.	7.1	67
7	Safety, Long-Term Results, and Predictors of Recurrence After Complete Endocardial Ventricular Tachycardia Substrate Ablation in Patients With Previous Myocardial Infarction. American Journal of Cardiology, 2013, 111, 499-505.	0.7	47
8	Ablation of Rotor Domains Effectively Modulates Dynamics of Human. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	43
9	Differential methylation of lncRNA <i>KCNQ1OT1</i> promoter polymorphism was associated with symptomatic cardiac long QT. Epigenomics, 2017, 9, 1049-1057.	1.0	27
10	Identification of Dominant Excitation Patterns and Sources of Atrial Fibrillation by Causality Analysis. Annals of Biomedical Engineering, 2016, 44, 2364-2376.	1.3	23
11	The dilemma of surgical or percutaneous approach in aortic stenosis: A reliable risk score is needed. American Heart Journal, 2010, 160, e1.	1.2	21
12	Differences in Ventriculoatrial Intervals During Entrainment and Tachycardia: A Simpler Method for Distinguishing Paroxysmal Supraventricular Tachycardia with Long Ventriculoatrial Intervals. Journal of Cardiovascular Electrophysiology, 2011, 22, 915-921.	0.8	20
13	High-rate pacing-induced atrial fibrillation effectively reveals properties of spontaneously occurring paroxysmal atrial fibrillation in humans. Europace, 2012, 14, 1560-1566.	0.7	20
14	KCNQ1 gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort. Molecular and Cellular Endocrinology, 2016, 427, 86-91.	1.6	19
15	Analysis of the High-Frequency Content in Human QRS Complexes by the Continuous Wavelet Transform: An Automatized Analysis for the Prediction of Sudden Cardiac Death. Sensors, 2018, 18, 560.	2.1	16
16	A scoring algorithm for the accurate differential diagnosis of regular wide QRS complex tachycardia. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 625-633.	0.5	16
17	Time-dependent responses to provocative testing with flecainide in the diagnosis of Brugada syndrome. Heart Rhythm, 2015, 12, 350-357.	0.3	15
18	Moderate Patient-Prosthesis Mismatch Predicts Cardiac Events and Advanced Functional Class in Young and Middle-Aged Patients Undergoing Surgery Due to Severe Aortic Stenosis. Journal of Cardiac Surgery, 2014, 29, 127-133.	0.3	14

DAVID CALVO

#	Article	IF	CITATIONS
19	The Prevalence of Patient-Prosthesis Mismatch Can Be Reduced Using the Trifecta Aortic Prosthesis. Annals of Thoracic Surgery, 2018, 105, 144-151.	0.7	13
20	Long-term prognosis of women with Brugada syndrome and electrophysiological study. Heart Rhythm, 2021, 18, 664-671.	0.3	13
21	Bloqueo intrahisiano durante el implante de la prótesis aórtica percutánea CoreValve. Revista Espanola De Cardiologia, 2011, 64, 168-169.	0.6	12
22	Insights for Stratification of Risk in Brugada Syndrome. European Cardiology Review, 2019, 14, 45-49.	0.7	12
23	Hypertrophic cardiomyopathy and athlete's heart: a tale of two entities. European Journal of Echocardiography, 2009, 10, 151-153.	2.3	11
24	Surveillance after cardiac arrest in patients with Brugada syndrome without an implantable defibrillator: An alarm effect of the previous syncope. International Journal of Cardiology, 2016, 218, 69-74.	0.8	11
25	Ventricular Tachycardia and Early Fibrillation in Patients With Brugada Syndrome and Ischemic Cardiomyopathy Show Predictable Frequency-Phase Properties on the Precordial ECG Consistent With the Respective Arrhythmogenic Substrate. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1133-1143.	2.1	10
26	Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. Europace, 2018, 20, f64-f71.	0.7	9
27	Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Heart Rhythm, 2020, 17, 1084-1091.	0.3	8
28	Differential Responses of the Septal Ventricle and the Atrial Signals During Ongoing Entrainment. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1201-1209.	2.1	7
29	The QT Interval Dynamic in a Human Experimental Model of Controlled Heart Rate and QRS Widening. Journal of Clinical Medicine, 2019, 8, 1417.	1.0	7
30	Contraste ecocardiográfico y seguridad clÃnica. Revista Espanola De Cardiologia, 2006, 59, 399-400.	0.6	6
31	Prevalence of positive ECG criteria in young competitive athletes: a single region experience. European Heart Journal, 2008, 29, 680-681.	1.0	6
32	EGC Diagnosis of Paroxysmal Supraventricular Tachycardias in Patients without Preexcitation. , 2011, 16, 85-95.		5
33	Mechanoelectric Feedback in the Ischemic Myocardium: An Interplay That Modulates Susceptibility to Fibrillation. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 168-170.	0.4	5
34	Characterization of a stepwise approach in cavotricuspid isthmus ablation for typical atrial flutter: A randomized study comparing three catheters. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1052-1058.	0.5	5
35	Spectral analysis of electrograms in a substrate modified by radiofrequency ablation reveals similarities between organized and disorganized atrial rhythms. Heart Rhythm, 2014, 11, 2306-2309.	0.3	4
36	Delta of the local ventriculo-atrial intervals at the septal location to differentiate tachycardia using septal accessory pathways from atypical atrioventricular nodal re-entry. Europace, 2018, 20, 1638-1646.	0.7	4

DAVID CALVO

#	Article	IF	CITATIONS
37	Spectral Analysis of the QT Interval Increases the Prediction Accuracy of Clinical Variables in Brugada Syndrome. Journal of Clinical Medicine, 2019, 8, 1629.	1.0	4
38	Sodium-Glucose Cotransporter-2 Inhibitors at Discharge from Cardiology Hospitalization Department: Decoding A New Clinical Scenario. Journal of Clinical Medicine, 2020, 9, 2600.	1.0	4
39	Inappropriate shock due to late dislocation of electrode. International Journal of Cardiology, 2015, 199, 229-231.	0.8	3
40	An elderly Jervell and Langeâ€Nielsen patient heterozygous compound for two new <i>KCNQ1</i> mutations. American Journal of Medical Genetics, Part A, 2017, 173, 749-752.	0.7	3
41	Prediction of ventricular arrhythmias in Brugada syndrome patients: is it time for automatized electrocardiogram analysis?. Europace, 2020, 22, 674-674.	0.7	3
42	Retroalimentación mecanoeléctrica del miocardio isquémico: un juego que modula su capacidad fibrilatoria. Revista Espanola De Cardiologia, 2013, 66, 168-170.	0.6	2
43	Smallâ€Caliber Lead Failure After Generator Exchange. Journal of Cardiovascular Electrophysiology, 2016, 27, 846-850.	0.8	2
44	Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 149-158.	0.6	1
45	Propagation of Sinus Waves in the Atrial Architecture. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	1
46	Association of age with clinical features and ablation outcomes of paroxysmal supraventricular tachycardias. Heart, 2022, 108, 1107-1113.	1.2	1
47	The Difficult Challenge of Assessing the Clinical Status of Octogenarians with Severe Aortic Stenosis. American Journal of Cardiology, 2010, 106, 753.	0.7	0
48	Letter by Lozano et al Regarding Articles, "Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves―and "Percutaneous Therapy for Valvular Heart Disease: A Huge Advance and a Huge Challenge to Do It Right― Circulation, 2011, 123, e15.	1.6	0
49	Routinary use of preoperative transthoracic echocardiography in abdominal aortic aneurysm, does it solve problems?. Journal of Thoracic Disease, 2017, 9, S442-S444.	0.6	Ο
50	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). Revista Espanola De Cardiologia (English Ed ), 2019, 72, 1020-1030.	0.4	0
51	The clinical impact of untreated slow ventricular tachycardia in patients carrying implantable cardiac defibrillators. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 103-111.	0.6	Ο
52	Frequency and Phase Domains Methods for Mechanisms of Fibrillation. , 2021, , 243-257.		0
53	A comprehensive formula for computing corrected QT intervals in patients with wide QRS. Journal of Electrocardiology, 2021, 66, 139-147.	0.4	0
54	Ex-post correction of pacemaker mode switch episodes in undersensed atrial fibrillation. Computers in Biology and Medicine, 2021, 134, 104480.	3.9	0

DAVID CALVO

#	Article	IF	CITATIONS
55	Nonpermanent atrial fibrillation in the new European Society of Cardiology guidelines. Response. Revista Espanola De Cardiologia (English Ed ), 2021, 75, 104-104.	0.4	0
56	Comments on the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Revista Espanola De Cardiologia (English Ed ), 2022, , .	0.4	0
57	Distinct spectral dynamics of implanted cardiac defibrillator signals in spontaneous termination of polymorphic ventricular tachycardia and fibrillation in patients with electrical and structural diseases. Europace, 0, , .	0.7	0